528 related articles for article (PubMed ID: 36400749)
1. Mutant p53 in cancer: from molecular mechanism to therapeutic modulation.
Chen X; Zhang T; Su W; Dou Z; Zhao D; Jin X; Lei H; Wang J; Xie X; Cheng B; Li Q; Zhang H; Di C
Cell Death Dis; 2022 Nov; 13(11):974. PubMed ID: 36400749
[TBL] [Abstract][Full Text] [Related]
2. Gain-of-function mutant p53 in cancer progression and therapy.
Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z
J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796
[TBL] [Abstract][Full Text] [Related]
3. Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.
Yue X; Zhao Y; Xu Y; Zheng M; Feng Z; Hu W
J Mol Biol; 2017 Jun; 429(11):1595-1606. PubMed ID: 28390900
[TBL] [Abstract][Full Text] [Related]
4. The ubiquitin ligase TRIM21 regulates mutant p53 accumulation and gain of function in cancer.
Liu J; Zhang C; Xu D; Zhang T; Chang CY; Wang J; Liu J; Zhang L; Haffty BG; Zong WX; Hu W; Feng Z
J Clin Invest; 2023 Mar; 133(6):. PubMed ID: 36749630
[TBL] [Abstract][Full Text] [Related]
5. The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins.
Wei S; Wang H; Lu C; Malmut S; Zhang J; Ren S; Yu G; Wang W; Tang DD; Yan C
J Biol Chem; 2014 Mar; 289(13):8947-59. PubMed ID: 24554706
[TBL] [Abstract][Full Text] [Related]
6. Pontin, a new mutant p53-binding protein, promotes gain-of-function of mutant p53.
Zhao Y; Zhang C; Yue X; Li X; Liu J; Yu H; Belyi VA; Yang Q; Feng Z; Hu W
Cell Death Differ; 2015 Nov; 22(11):1824-36. PubMed ID: 25857266
[TBL] [Abstract][Full Text] [Related]
7. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.
Iyer SV; Parrales A; Begani P; Narkar A; Adhikari AS; Martinez LA; Iwakuma T
Oncotarget; 2016 Feb; 7(5):5401-15. PubMed ID: 26700961
[TBL] [Abstract][Full Text] [Related]
8. Gain of function mutant p53 protein activates AKT through the Rac1 signaling to promote tumorigenesis.
Yue X; Wu F; Li Y; Liu J; Boateng M; Mandava K; Zhang C; Feng Z; Gao J; Hu W
Cell Cycle; 2020 Jun; 19(11):1338-1351. PubMed ID: 32275841
[TBL] [Abstract][Full Text] [Related]
9. Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis.
Pavlakis E; Neumann M; Merle N; Wieboldt R; Wanzel M; Ponath V; Pogge von Strandmann E; Elmshäuser S; Stiewe T
J Exp Clin Cancer Res; 2023 Aug; 42(1):203. PubMed ID: 37563605
[TBL] [Abstract][Full Text] [Related]
10. Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis.
Zheng T; Wang J; Zhao Y; Zhang C; Lin M; Wang X; Yu H; Liu L; Feng Z; Hu W
Nat Commun; 2013; 4():2996. PubMed ID: 24356649
[TBL] [Abstract][Full Text] [Related]
11. DNA2 Nuclease Inhibition Confers Synthetic Lethality in Cancers with Mutant p53 and Synergizes with PARP Inhibitors.
Folly-Kossi H; Graves JD; Garan LAW; Lin FT; Lin WC
Cancer Res Commun; 2023 Oct; 3(10):2096-2112. PubMed ID: 37756561
[TBL] [Abstract][Full Text] [Related]
12. Proteasomal and autophagy-mediated degradation of mutp53 proteins through mitochondria-targeting aggregation-induced-emission materials.
Wang M; Yang Z; Song Y; Wei P; Ishiwme N; Wang L; Zhang H; Jing M; Gao M; Wen L; Zhang Y
Acta Biomater; 2022 Sep; 150():402-412. PubMed ID: 35931280
[TBL] [Abstract][Full Text] [Related]
13. BAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and function.
Yue X; Zhao Y; Liu J; Zhang C; Yu H; Wang J; Zheng T; Liu L; Li J; Feng Z; Hu W
Elife; 2015 Aug; 4():. PubMed ID: 26271008
[TBL] [Abstract][Full Text] [Related]
14. Identification of a druggable protein-protein interaction site between mutant p53 and its stabilizing chaperone DNAJA1.
Tong X; Xu D; Mishra RK; Jones RD; Sun L; Schiltz GE; Liao J; Yang GY
J Biol Chem; 2021; 296():100098. PubMed ID: 33208462
[TBL] [Abstract][Full Text] [Related]
15. Gain-of-function miRNA signature by mutant p53 associates with poor cancer outcome.
Zhang Y; Hu Y; Fang JY; Xu J
Oncotarget; 2016 Mar; 7(10):11056-66. PubMed ID: 26840456
[TBL] [Abstract][Full Text] [Related]
16. Mutant p53 Gain of Function and Chemoresistance: The Role of Mutant p53 in Response to Clinical Chemotherapy.
He C; Li L; Guan X; Xiong L; Miao X
Chemotherapy; 2017; 62(1):43-53. PubMed ID: 27322648
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion.
Schulz-Heddergott R; Stark N; Edmunds SJ; Li J; Conradi LC; Bohnenberger H; Ceteci F; Greten FR; Dobbelstein M; Moll UM
Cancer Cell; 2018 Aug; 34(2):298-314.e7. PubMed ID: 30107178
[TBL] [Abstract][Full Text] [Related]
18. Targeting Mutant-p53 for Cancer Treatment: Are We There Yet?
Lim DV; Woo WH; Lim JX; Loh XY; Soh HT; Lim SYA; Lee ZY; Yow HY; Hamzah SB; Sellappans R; Foo JB
Curr Mol Pharmacol; 2024; 17(1):e140923221042. PubMed ID: 37711005
[TBL] [Abstract][Full Text] [Related]
19. Glutathionylation-dependent proteasomal degradation of wide-spectrum mutant p53 proteins by engineered zeolitic imidazolate framework-8.
Zhang Y; Huang X; Wang L; Cao C; Zhang H; Wei P; Ding H; Song Y; Chen Z; Qian J; Zhong S; Liu Z; Wang M; Zhang W; Jiang W; Zeng J; Yao G; Wen LP
Biomaterials; 2021 Apr; 271():120720. PubMed ID: 33639563
[TBL] [Abstract][Full Text] [Related]
20. Precise pancreatic cancer therapy through targeted degradation of mutant p53 protein by cerium oxide nanoparticles.
Zhang H; Zhang W; Hu B; Qin X; Yi T; Ye Y; Huang X; Song Y; Yang Z; Qian J; Zhang Y
J Nanobiotechnology; 2023 Apr; 21(1):117. PubMed ID: 37005668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
